CCR5 expression on cells from HLA-matched unrelated marrow donors and graft-versus-host disease.
作者信息
Ma Qing, Gooley Ted A, Storb Rainer F
出版信息
Biol Blood Marrow Transplant. 2010 Jan;16(1):132-3. doi: 10.1016/j.bbmt.2009.05.017. Epub 2009 Jul 12.
Abstract
摘要
相似文献
1
CCR5 expression on cells from HLA-matched unrelated marrow donors and graft-versus-host disease.
Biol Blood Marrow Transplant. 2010 Jan;16(1):132-3. doi: 10.1016/j.bbmt.2009.05.017. Epub 2009 Jul 12.
2
High-risk HLA alleles for severe acute graft-versus-host disease and mortality in unrelated donor bone marrow transplantation.
Haematologica. 2016 Apr;101(4):491-8. doi: 10.3324/haematol.2015.136903. Epub 2016 Jan 14.
3
4
Cord blood transplantation for cure of HIV infections.
Stem Cells Transl Med. 2013 Sep;2(9):635-7. doi: 10.5966/sctm.2012-0089. Epub 2013 Jul 24.
5
Mapping of susceptibility and protective loci for acute GVHD in unrelated HLA-matched bone marrow transplantation donors and recipients using 155 microsatellite markers on chromosome 22.
Immunogenetics. 2007 Feb;59(2):99-108. doi: 10.1007/s00251-006-0186-2. Epub 2007 Jan 3.
6
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.
Haematologica. 2017 Feb;102(2):391-400. doi: 10.3324/haematol.2016.144139. Epub 2016 Oct 20.
7
Genetic factors influence the development of acute graft-versus-host disease in adults undergoing allogeneic bone marrow transplantation.
Transplant Proc. 1992 Oct;24(5):2269.
8
The recipient CCR5 variation predicts survival outcomes after bone marrow transplantation.
Transpl Immunol. 2017 Jun;42:34-39. doi: 10.1016/j.trim.2017.05.003. Epub 2017 May 6.
9
Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study.
Lancet Haematol. 2019 Nov;6(11):e585-e596. doi: 10.1016/S2352-3026(19)30154-1. Epub 2019 Sep 5.
10
Outcome of allogeneic bone marrow transplantation from unrelated donors for adult Philadelphia chromosome-negative acute lymphocytic leukemia in first complete-remission.
Int J Hematol. 2010 Apr;91(3):419-25. doi: 10.1007/s12185-010-0509-9. Epub 2010 Feb 10.
引用本文的文献
1
Blockade of CCR5 and CXCR3 attenuates murine acute graft-versus-host disease through modulating donor-derived T-cell distribution and function.
Int Immunol. 2024 Sep 10;36(10):541-552. doi: 10.1093/intimm/dxae033.
2
γδ T Cells May Aggravate Acute Graft-Versus-Host Disease Through CXCR4 Signaling After Allogeneic Hematopoietic Transplantation.
Front Immunol. 2021 Jul 14;12:687961. doi: 10.3389/fimmu.2021.687961. eCollection 2021.
3
The Biological and Clinical Relevance of G Protein-Coupled Receptors to the Outcomes of Hematopoietic Stem Cell Transplantation: A Systematized Review.
Int J Mol Sci. 2019 Aug 9;20(16):3889. doi: 10.3390/ijms20163889.
4
Achievement of Tolerance Induction to Prevent Acute Graft-vs.-Host Disease.
Front Immunol. 2019 Mar 6;10:309. doi: 10.3389/fimmu.2019.00309. eCollection 2019.
5
Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease Prophylaxis.
Biol Blood Marrow Transplant. 2018 Mar;24(3):594-599. doi: 10.1016/j.bbmt.2017.10.028. Epub 2017 Oct 20.
6
Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis.
Blood. 2017 Feb 16;129(7):906-916. doi: 10.1182/blood-2016-08-735076. Epub 2017 Jan 5.
7
Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.
N Engl J Med. 2012 Jul 12;367(2):135-45. doi: 10.1056/NEJMoa1201248.
8
The effect of the CCR5-delta32 deletion on global gene expression considering immune response and inflammation.
J Inflamm (Lond). 2011 Oct 26;8:29. doi: 10.1186/1476-9255-8-29.
9
Chemokine receptor CCR5 mediates alloimmune responses in graft-versus-host disease.
Biol Blood Marrow Transplant. 2010 Mar;16(3):311-9. doi: 10.1016/j.bbmt.2009.12.002. Epub 2009 Dec 16.
本文引用的文献
1
The chemokine system and CCR5 antagonists: potential in HIV treatment and other novel therapies.
J Clin Pharm Ther. 2009 Apr;34(2):147-60. doi: 10.1111/j.1365-2710.2008.00978.x.
2
Chemokine receptor-dependent alloresponses.
Immunol Rev. 2003 Dec;196:37-50. doi: 10.1046/j.1600-065x.2003.00084.x.
3
Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction.
Nat Immunol. 2003 Feb;4(2):154-60. doi: 10.1038/ni879. Epub 2003 Jan 13.
4
CC chemokine receptor 5 and renal-transplant survival.
Lancet. 2001 Jun 2;357(9270):1758-61. doi: 10.1016/s0140-6736(00)04898-4.
5
Chemokines as regulators of T cell differentiation.
Nat Immunol. 2001 Feb;2(2):102-7. doi: 10.1038/84205.
6
7
Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease.
J Clin Invest. 1999 Jul;104(1):49-57. doi: 10.1172/JCI6642.
8
Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia.
N Engl J Med. 1998 Apr 2;338(14):962-8. doi: 10.1056/NEJM199804023381405.
9
CCR5-delta 32 gene deletion in HIV-1 infected patients.
Lancet. 1997 Sep 6;350(9079):741; author reply 742. doi: 10.1016/S0140-6736(05)63551-9.
10
Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study.
Science. 1997 Aug 15;277(5328):959-65. doi: 10.1126/science.277.5328.959.
Zotero 插件